PlexusDx recommends that all patients with inflammatory bowel or colon history consult their gastroenterologist or primary care physician before initiating GLP-1 therapy to establish a personalized risk-benefit assessment
Cancer , 97 , 21-27, doi: Li, M., Zhang, Z., Yuan, J., Zhang, Y., and Jin, X
Beneficial effect of selenium doped carbon quantum dots supplementation on the in vitro development competence of ovine oocytes
Healthcare practitioners at Formation planning to integrate peptide-based therapies into clinical practice must obtain professional certification and comprehensive training protocols
If you are starting a broader GLP-1 plan, it can help to review how to get the most out of your GLP-1 treatment
If a patient does not respond to the first-line therapy (amitriptyline, cyproheptadine, and/or propranolol) the following options should be considered: (1) presence of persisting triggers (e.g., psychological stressors) and comorbid conditions (e.g., anxiety, POTS) or missed underlying disorders (e.g., hydronephrosis, chronic sinusitis, acute appendicitis, intestinal malrotation with volvulus, CNS tumors, metabolic crises) and toxic exposure (e.g., cannabis)
